Primum non nocere – Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
DOI:
https://doi.org/10.11606/s1518-8787.2020054002631Keywords:
Coronavirus Infections, Chloroquine, toxicity, Hydroxychloroquine, toxicity, Contraindications, DrugAbstract
ABSTRACT Chloroquine (CQ) and its analog hydroxychloroquine (HCQ) were recently included in several clinical trials as potential prophylactic and therapeutic options for SARS-CoV-2 infection/covid-19. However, drug effectiveness in preventing, treating, or slowing the progression of the disease is still unknown. Despite some initial promising in vitro results, rigorous pre-clinical animal studies and randomized clinical trials have not been performed yet. On the other hand, while the potential effectiveness of CQ/HCQ is, at best, hypothetical, their side effects are factual and most worrisome, particularly when considering vulnerable groups of patients being treated with these drugs. In this comment, we briefly explain the possible mechanisms of action of CQ/HCQ for treating other diseases, possible actions against covid-19, and their potent side effects, in order to reinforce the necessity of evaluating the benefit-risk balance when widely prescribing these drugs for SARS-CoV-2 infection/covid-19. We conclude by strongly recommending against their indiscriminate use. DESCRIPTORS: Coronavirus Infections. Chloroquine, toxicity. Hydroxychloroquine, toxicity. Contraindications, Drug.
References
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71. https://doi.org/10.1038/s41422-020-0282-0
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [published online ahead of print, 2020 Mar 20]. Int J Antimicrob Agents. 2020;105949. https://doi.org/10.1016/j.ijantimicag.2020.105949
Sandhu VK, Weisman MH. Hydroxychloroquine - how much Is too much? J Rheumatol. 2019;46(4):340-2. https://doi.org/10.3899/jrheum.180639
Schaer CA, Laczko E, Schoedon G, Schaer DJ, Vallelian F. Chloroquine interference with hemoglobin endocytic trafficking suppresses adaptive heme and iron homeostasis in macrophages: the paradox of an antimalarial agent. Oxid Med Cell Longev. 2013;2013:870472. https://doi.org/10.1155/2013/870472
Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003;3(11):722-7. https://doi.org/10.1016/s1473-3099(03)00806-5
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. https://doi.org/10.1038/s41421-020-0156-0
Mehra MR, Desai SS, Ruschitzka F, Patel MD. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020; https://doi.org/10.1016/S0140-6736(20)31180-6
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13. https://doi.org/10.1016/S0140-6736(20)30211-7
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393 https://doi.org/10.1016/j.clim.2020.108393
Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020;55(5):105951. https://doi.org/10.1016/j.ijantimicag.2020.105951
World Health Organization. Solidarity clinical trial for COVID-19 treatments. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments. Date: March 18, 2020 Date accessed April 12, 2020.
US National Institutes of Health. COVID-19 Treatment Guidelines. Overview and spectrum of COVID-19: summary recommendations. Bethesda, MD: NIH; 2020 [cited 2020 April 22]. Available from: https://covid19treatmentguidelines.nih.gov/overview/
World Health Organization. Q&A : Hydroxychloroquine and COVID-19. https://www.who.int/news-room/q-a-detail/q-a-hydroxychloroquine-and-covid-19#. Date: May 26, 2020 Date accessed May 29, 2020.
Abdel Galil SM. Hydroxychloroquine-induced toxic hepatitis in a patient with systemic lupus erythematosus: a case report. Lupus. 2015;24(6):638-40. https://doi.org/10.1177/0961203314561667
Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye (Lond). 2017;31(6):828-45. https://doi.org/10.1038/eye.2016.298
Casado E, Gratacós J, Tolosa C, Martínez JM, Ojanguren I, Ariza A, et al. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis. 2006;65(3):385-90. https://doi.org/10.1136/ard.2004.023200
Yogasundaram H, Putko BN, Tien J, Paterson DI, Cujec B, Ringrose J, et al. Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. Can J Cardiol. 2014;30(12):1706-15. https://doi.org/10.1016/j.cjca.2014.08.016.
US Food and Drug Administration. Coronavirus (COVID-19) Update: Daily Roundup April 7, 2020. Silver Spring, MD: FDA; 2020 [cited 2020 April 10]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-7-2020
Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol. 2000;27(12):2927-31.
Azimian M, Gultekin SH, Hata JL, Atkinson JB, Ely KA, Fuchs HA, et al. Fatal antimalarial-induced cardiomyopathy: report of 2 cases. J Clin Rheumatol. 2012;18(7):363-6. https://doi.org/10.1097/RHU.0b013e31826852db
Marrelli MT, Brotto M. The effect of malaria and anti-malarial drugs on skeletal and cardiac muscles. Malar J.2016;15:524. https://doi.org/10.1186/s12936-016-1577-y
Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with Coronavirus Disease 2019 (COVID-19) [published online ahead of print, 2020 Mar 27]. JAMA Cardiol. 2020:e201017. https://doi.org/10.1001/jamacardio.2020.1017
Joyce E, Fabre A, Mahon N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. Eur Heart J Acute Cardiovasc Care. 2013;2(1):77-83. https://doi.org/10.1177/2048872612471215
Published
Issue
Section
License
Copyright (c) 2020 Claudia Biguett, Marco Broto, Mauro Toledo Marrelli
This work is licensed under a Creative Commons Attribution 4.0 International License.
